Physician profile
Mark S Barats
NPI 1720134695
$31,596.19
in general payments reported to CMS, 2019-2025
71 companies · $3,601 in 2025
The $3,601 reported for 2025 was more than what 92% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,298 · 2020: $3,449 · 2021: $5,895 · 2022: $6,907 · 2023: $3,889 · 2024: $4,556 · 2025: $3,601.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,046.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $6,537.07 | 2019-2023 | Krystexxa, Tepezza |
| Amgen INC. | $3,549.19 | 2019-2025 | Evenity, Krystexxa, Prolia |
| Abbvie INC. | $2,943.51 | 2019-2025 | Vraylar, Linzess, Viberzi |
| Novartis Pharmaceuticals Corporation | $1,438.48 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,412.74 | 2019-2025 | Farxiga, Tezspire, Breztri |
| Amarin Pharma, INC. | $1,256.49 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,169.05 | 2019-2025 | Xifaxan, Trulance |
| Ardelyx, INC. | $845.83 | 2022-2025 | Ibsrela |
| Lundbeck LLC | $799.31 | 2020-2025 | Vyepti, Rexulti |
| Eisai INC. | $755.20 | 2020-2025 | |
| Pfizer INC. | $731.33 | 2019-2025 | |
| Novo Nordisk INC | $667.39 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $662.66 | 2019-2025 | Mounjaro, Zepbound, Kisunla |
| Ironwood Pharmaceuticals, INC | $631.11 | 2019-2025 | Linzess |
| Almatica Pharma LLC | $585.35 | 2022-2025 | Loreev Xr, Teriparatide, Gralise |
Show all 71 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Barats listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.